trial · primary record
MDX2003
Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 180 |
| Primary completion | 2030-04 |
| Primary endpoint | Part A only- Identify the Maximum Tolerated Dose (MTD) for expansion for further development of MDX2003 |
| Registry ID | NCT07249905 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:26.939Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07249905
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.